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Medullary carcinoma of the thyroid (MTC) represents
5-10% of differentiated thyroid cancers. It derives from the
thyroid C-cells which produce calcitonin and are of neu-
roendocrine origin. It is a rather rare tumour and is
accompanied by considerable mortality as it has frequently
already metastasised at diagnosis and is not sensitive to
either radiation or chemotherapy. Recently it has been
shown that MTC is not infrequent in multinodular thyroid
disease and thus universal calcitonin screening has been
suggested in the diagnostic workup of thyroid nodules.
The prognosis of the disease has recently improved as
many of the newly diagnosed cases are now small, non-
invasive tumours, that probably were previously missed.
MTC is an interesting tumour as it occurs in a familial
form in >25% of the cases, as part of the multiple endo-
crine neoplasia 2 syndromes (MEN2). When familial MTC
may occur in combination with pheochromocytomas and,
more rarely, with primary hyperparathyroidism. Recent
advances in MTC management include preclinical diagno-
sis using molecular techniques in the case of familial dis-
ease and prophylactic thyroidectomy in asymptomatic
gene carriers. The gene responsible for transmission of the
MEN2 is the ret proto-oncogene, which is a membrane
receptor tyrosine kinase; its physiological role is the trans-
mission of neural signals during development. Most of the
mutations which are found in MEN2 syndromes are clus-
tered in the cysteine rich extracellular domain of the pro-
tein and either cause dimerisation or ligand-independent
activation. Novel previously unknown ret mutations across
many regions of the gene are currently being recognized.
Mutation analysis should be performed in all cases of
MTC because these sometimes represent unrecognized
familial disease. When a mutation is identified, family
members are screened and carriers are offered prophylac-
tic thyroidectomy at a young age. The type of mutation is
classified into more or less aggressive and it is important
for the penetrance of the disease. The majority of experts
suggest prophylactic surgery at 5-10 years, especially when
the specific mutation associates with risk for earlier MTC
development and more aggressive disease. Several recent
publications have examined the success/cure rate of pro-
phylactic treatment.
One important development in the field of MTC con-
cerns the use of newer antineoplastic agents, including
agents targeting the molecular pathways involved in its
pathogenesis. Novel multi targeted tyrosine kinase inhibi-
tors are being tested in advanced disease in the context of
clinical trials. Recent publications indicate that a substan-
tial proportion of patients with advanced disease will stabi-
lize with the use of these promising agents. Patients with
familial disease appear to respond better to therapy with
tyrosine kinase inhibitors. Combination therapies are also
being tested.
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